论文部分内容阅读
目的检测bcl-2和bax蛋白在前列腺癌组织中的表达情况,并探讨其与前列腺癌临床病理特征的关系。方法采用免疫组化检测bcl-2和bax蛋白在32例前列腺癌及癌旁组织中的表达情况。结果bcl-2和bax蛋白在前列腺癌组织中的阳性表达率分别为53.1%和43.6%(17/32和14/32),而在癌旁组织中的阳性表达率分别为6.3%和100%(2/32和32/32),两者比较有显著性差异(P<0.05)。bcl-2蛋白的表达与前列腺癌分化程度及临床分期密切相关(P<0.05)。bcl-2蛋白的表达与前列腺癌患者年龄无显著相关性(P>0.05)。结论bcl-2和bax蛋白可能参与前列腺癌的发生发展,有望成为前列腺癌诊断和判断预后的分子标志物。
Objective To detect the expression of bcl-2 and bax protein in prostate cancer and to explore its relationship with the clinicopathological features of prostate cancer. Methods Immunohistochemistry was used to detect the expression of bcl-2 and bax proteins in 32 cases of prostate cancer and adjacent normal tissues. Results The positive rates of bcl-2 and bax in prostate cancer tissues were 53.1% and 43.6% (17/32 and 14/32), respectively, while the positive rates of bcl-2 and bax in adjacent tissues were 6.3% and 100% respectively (2/32 and 32/32), there was a significant difference between the two (P <0.05). The expression of bcl-2 protein was closely related to the degree of differentiation and clinical stage of prostate cancer (P <0.05). There was no significant correlation between the expression of bcl-2 protein and the age of prostate cancer patients (P> 0.05). Conclusions The expressions of bcl-2 and bax proteins may be involved in the development of prostate cancer and may become molecular markers for the diagnosis and prognosis of prostate cancer.